Stopping Selank: What Studies Report About Discontinuation

Searches for "Selank withdrawal" usually mix two very different questions: whether stopping Selank produces a withdrawal syndrome, and whether Selank has been studied as an agent given during someone else's withdrawal. The published literature answers the second question far more directly than the first. This page summarises what the verified studies actually measured after administration ended, and marks clearly where nothing was measured at all. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

The short answer from the literature

Across the studies collected here, the dominant design was: administer the peptide, measure an outcome during or immediately after the administration period, and stop. Follow-up windows after cessation — the observations that would reveal rebound, tolerance reversal or discontinuation effects — were not the focus of any of these reports. That absence is itself the finding most relevant to a "withdrawal" search. It does not mean discontinuation is uneventful; it means the question has not been the subject of a dedicated published experiment in this evidence set.

Two different meanings of "Selank withdrawal"

1. Selank studied inside a withdrawal state

The clearest withdrawal-related result comes from a rat morphine study. Researchers reported that Selank, a peptide analogue of tuftsin, attenuated aversive signs of morphine withdrawal in rats (PMID 36322304). In that design, the withdrawal syndrome belonged to morphine; Selank was the intervention being tested against it. The study did not characterise a Selank withdrawal syndrome, and its findings should not be read backwards as evidence about what happens when Selank itself is stopped.

A related theme appears in an ethanol model, where the study reported that Selank protected against ethanol-induced memory impairment and was associated with changes in BDNF content in the hippocampus and prefrontal cortex of rats (PMID 31625062). Again, the toxic exposure under study was ethanol. These papers place Selank in the literature on substance-related harm as a candidate modulator, not as a substance with a documented discontinuation syndrome of its own.

2. Discontinuation of Selank itself

For this second meaning, the verified papers offer no dedicated experiment. None of them was designed as a washout study, a cessation study, a tapering comparison or a dependence-liability assessment. Where administration periods ended, the published summaries described endpoint measurements rather than a subsequent observation window.

What the clinical literature covered

The main clinical entry in this set is a Russian-language report on optimising the treatment of anxiety disorders with Selank (PMID 26356395). It sits in the clinical-course literature: how the peptide was used within anxiety-disorder treatment, rather than what happened to patients after the course finished. Readers looking for structured post-treatment follow-up — relapse rates, rebound anxiety scores, insomnia after cessation, or a comparison against benzodiazepine discontinuation — will not find those endpoints framed as the study's subject.

That gap matters because anxiety pharmacology is one of the fields where discontinuation effects are most carefully tracked for other drug classes. A separate rat study reported that Selank enhanced the effect of diazepam in reducing anxiety under unpredictable chronic mild stress conditions (PMID 28280289). Combination findings like this one raise obvious follow-on questions about what happens when one component of a combination stops — but the study measured the combination's anxiolytic effect, not the consequences of ending it.

Mechanism studies: what they do and do not say about washout

Several papers describe molecular actions that, in principle, would determine how quickly effects fade after the last administration. They were not run as time-course-to-baseline experiments, so they constrain speculation rather than settle it.

• GABAergic gene expression. In IMR-32 cells, the study reported that GABA, Selank and olanzapine affected the expression of genes involved in GABAergic neurotransmission (PMID 28293190). Transcriptional effects are frequently reversible, but the paper did not report a post-exposure recovery curve.
• Synaptic activity. Researchers examined the effect of Selank on spontaneous synaptic activity of rat hippocampal CA1 neurons (PMID 28361410), an acute electrophysiological readout rather than a chronic-then-withdraw design.
• Network-level imaging. A functional connectomic study examined Selank and Semax effects on brain functional connectivity (PMID 32342318). Connectivity methods could in principle detect a post-cessation state, but the report addressed the effects of administration.
• Review-level synthesis. A review of the molecular aspects of heptapeptide Selank biological activity summarised proposed anxiolytic mechanisms (PMID 30255741) without presenting a discontinuation dataset.

Study-by-study: was anything measured after dosing ended?

The table reflects what the published titles and abstracts describe. Full texts occasionally contain observation details that abstracts omit, so the right reading is "not reported as a study aim," not "proven absent."

Rebound and tolerance: what studies report

Rebound means a measured outcome overshooting baseline in the wrong direction once an agent is removed — for example, anxiety scores rising above pre-treatment values. Tolerance means a diminishing effect during continued administration. Neither endpoint appears as a stated result in this evidence set. Chronic-stress studies did run over extended periods — including reports on cytokine levels under "social" stress conditions (PMID 32621722) and on liver morphology under chronic foot-shock stress (PMID 31243679) — but those designs measured effects of the stress-plus-peptide condition rather than tracking animals after the peptide was withdrawn.

The morphine study is the closest thing to a dependence-relevant signal, and it points the other way: the study reported that aversive withdrawal signs were attenuated when Selank was given (PMID 36322304). Interpreting that as evidence that Selank itself is free of discontinuation effects would be an unsupported leap; the experiment simply was not asked that question.

Adverse Events After Cessation: What Studies Report

No verified study in this set reported adverse events occurring after Selank administration ended. There is no published catalogue in these papers of post-cessation insomnia, irritability, mood change, autonomic symptoms or laboratory abnormalities attributable to stopping. The safety-adjacent data that do exist were collected during administration: for instance, researchers examined liver morphological parameters in stressed rats receiving Selank (PMID 31243679), and an immune-signalling study examined cytokine levels in a social-stress model (PMID 32621722). Organ- and immune-level readouts during dosing are not substitutes for cessation surveillance, and neither paper was framed as one.

Anecdotal reports circulating outside the literature are not evidence of the type summarised here; they lack controls, blinding, verified product identity and systematic outcome measurement, so they cannot establish whether an experience follows from stopping a peptide or from something else entirely.

Where no study examined it

To be explicit about the gaps, the following questions have no answer in the verified papers:

1. Whether anxiety, sleep or mood measures return to baseline, undershoot or overshoot after a course of Selank ends.
2. How long any molecular change — including the GABAergic gene-expression effects reported in cells (PMID 28293190) or the BDNF changes reported in rat brain regions (PMID 31625062) — persists after the last administration.
3. Whether abrupt cessation differs from gradual reduction on any measured outcome.
4. Whether physical dependence or drug-seeking behaviour develops with repeated administration.
5. Whether stopping Selank while a co-administered agent continues alters outcomes, a question raised but not tested by the diazepam combination study (PMID 28280289).
6. Whether post-cessation trajectories differ in disease models such as the 6-OHDA parkinsonism model in which behavioural effects were reported (PMID 28702721).

What a discontinuation study would need to include

Describing study design is not guidance about personal use; it is a way of judging future papers. A cessation-focused experiment would typically specify a defined administration period, a randomised abrupt-stop versus continued-dosing comparison, blinded outcome assessors, and repeated measurement across a washout window long enough to capture both return to baseline and any overshoot. Behavioural endpoints of the kind used in learning and memory work (PMID 20919548) and network-level imaging of the kind used in the connectomic analysis (PMID 32342318) are both technically capable of being run post-cessation; they simply have not been reported that way here.

Key takeaways

• The verified literature describes Selank during administration, not after it stops.
• The one clearly withdrawal-related result concerns morphine withdrawal in rats, where the study reported attenuation of aversive signs (PMID 36322304).
• No rebound, tolerance or dependence endpoint was reported in this set.
• No post-cessation adverse-event data were reported in this set.
• Reviews summarise proposed mechanisms (PMID 30255741) but do not fill the discontinuation gap.

Selank is not an approved drug in the United States and material sold under that name is commonly labelled for research use only. Questions about starting, continuing or stopping anything belong with a licensed clinician who knows the individual case.

References

• Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats (Bulletin of Experimental Biology and Medicine, 2022)
• [Optimization of the treatment of anxiety disorders with selank] (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015)
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (Behavioural Neurology, 2017)
• Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats (Bulletin of Experimental Biology and Medicine, 2019)
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells (Frontiers in Pharmacology, 2017)
• Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons (Bulletin of Experimental Biology and Medicine, 2017)
• The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress (Current Reviews in Clinical and Experimental Pharmacology, 2021)
• Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress (Bulletin of Experimental Biology and Medicine, 2019)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• [Experimental optimization of learning and memory processes by selank] (Eksperimental'naia i klinicheskaia farmakologiia, 2010)
• Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity (Protein and Peptide Letters, 2018)